Literature DB >> 34294205

Targeting TMEM16A-encoded Ca2+-activated Cl- channels: a new paradigm for antihypertensive therapy?

Normand Leblanc1.   

Abstract

Hypertension is the leading risk factor for the development of heart diseases and stroke. Many hypertensive patients experience undesirable side effects to conventional antihypertensive pharmacotherapy. Cil et al. documented the antihypertensive profile of a novel molecule, TMinh-23 (2-bromodifluoroacetylamino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide), in the spontaneously hypertensive rat model of systemic hypertension. They showed that this agent reduces blood pressure by inhibiting transmembrane member 16A-encoded calcium-activated chloride channels in vascular myocytes from resistance arteries. If validated, TMinh-23 could become a useful clinical tool.
Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34294205      PMCID： PMC8500664          DOI： 10.1016/j.kint.2021.04.040

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   18.998


  9 in total

1.  Disruption of vascular Ca2+-activated chloride currents lowers blood pressure.

Authors:  Christoph Heinze; Anika Seniuk; Maxim V Sokolov; Antje K Huebner; Agnieszka E Klementowicz; István A Szijártó; Johanna Schleifenbaum; Helga Vitzthum; Maik Gollasch; Heimo Ehmke; Björn C Schroeder; Christian A Hübner
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

Review 2.  Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50.

Authors:  Simon B Dimmitt; Hans G Stampfer; Jennifer H Martin; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2019-08-19       Impact factor: 4.335

3.  Antihypertensive Agents in Older Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Mohammad Hassan Murad; Laura Larrea-Mantilla; Abdullah Haddad; Gabriela Spencer-Bonilla; Valentina Serrano; Rene Rodriguez-Gutierrez; Neri Alvarez-Villalobos; Khaled Benkhadra; Michael R Gionfriddo; Larry J Prokop; Juan P Brito; Oscar J Ponce
Journal:  J Clin Endocrinol Metab       Date:  2019-05-01       Impact factor: 5.958

4.  Downregulation of TMEM16A calcium-activated chloride channel contributes to cerebrovascular remodeling during hypertension by promoting basilar smooth muscle cell proliferation.

Authors:  Mi Wang; Hui Yang; Ling-Yun Zheng; Zheng Zhang; Yong-Bo Tang; Guan-Lei Wang; Yan-Hua Du; Xiao-Fei Lv; Jie Liu; Jia-Guo Zhou; Yong-Yuan Guan
Journal:  Circulation       Date:  2012-01-03       Impact factor: 29.690

5.  Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension.

Authors:  Rita Papp; Chandran Nagaraj; Diana Zabini; Bence M Nagy; Miklós Lengyel; Davor Skofic Maurer; Neha Sharma; Bakytbek Egemnazarov; Gabor Kovacs; Grazyna Kwapiszewska; Leigh M Marsh; Andelko Hrzenjak; Gerald Höfler; Miroslava Didiasova; Malgorzata Wygrecka; Laura K Sievers; Peter Szucs; Péter Enyedi; Bahil Ghanim; Walter Klepetko; Horst Olschewski; Andrea Olschewski
Journal:  Eur Respir J       Date:  2019-06-05       Impact factor: 16.671

Review 6.  Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Salim S Virani; Clifton W Callaway; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Stephanie E Chiuve; Mary Cushman; Francesca N Delling; Rajat Deo; Sarah D de Ferranti; Jane F Ferguson; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Pamela L Lutsey; Jason S Mackey; David B Matchar; Kunihiro Matsushita; Michael E Mussolino; Khurram Nasir; Martin O'Flaherty; Latha P Palaniappan; Ambarish Pandey; Dilip K Pandey; Mathew J Reeves; Matthew D Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Uchechukwu K A Sampson; Gary M Satou; Svati H Shah; Nicole L Spartano; David L Tirschwell; Connie W Tsao; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2018-01-31       Impact factor: 29.690

7.  Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A).

Authors:  Eric C Truong; Puay W Phuan; Amanda L Reggi; Loretta Ferrera; Luis J V Galietta; Sarah E Levy; Alannah C Moises; Onur Cil; Elena Diez-Cecilia; Sujin Lee; Alan S Verkman; Marc O Anderson
Journal:  J Med Chem       Date:  2017-05-24       Impact factor: 7.446

Review 8.  Molecular and functional significance of Ca(2+)-activated Cl(-) channels in pulmonary arterial smooth muscle.

Authors:  Normand Leblanc; Abigail S Forrest; Ramon J Ayon; Michael Wiwchar; Jeff E Angermann; Harry A T Pritchard; Cherie A Singer; Maria L Valencik; Fiona Britton; Iain A Greenwood
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

9.  A small molecule inhibitor of the chloride channel TMEM16A blocks vascular smooth muscle contraction and lowers blood pressure in spontaneously hypertensive rats.

Authors:  Onur Cil; Xiaolan Chen; Henry R Askew Page; Samuel N Baldwin; Maria C Jordan; Pyone Myat Thwe; Marc O Anderson; Peter M Haggie; Iain A Greenwood; Kenneth P Roos; Alan S Verkman
Journal:  Kidney Int       Date:  2021-04-06       Impact factor: 18.998
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.